Tscan therapeutics to participate in upcoming investor conferences

Waltham, mass., aug. 29, 2024 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biotechnology company focused on the development of t cell receptor (tcr)-engineered t cell (tcr-t) therapies for the treatment of patients with cancer, today announced that the company will participate in the following upcoming investor conferences:
TCRX Ratings Summary
TCRX Quant Ranking